publication venue for
- The practice of evidence based laboratory medicine among worldwide medical laboratory professionals: Competencies and need of training 2019
- Patient with macrocomplexes for both creatine kinase and cardiac troponin reveals the importance of immunoassay methods for macrotroponin detection. 562:119885-119885. 2024
- An interference yielding divergent high-sensitivity cardiac troponin results on different instruments from the same manufacturer. 548:117450-117450. 2023
- Discrepant high-sensitivity cardiac troponin I concentrations when measured on the Abbott Alinity ci versus the Abbott Architect system. 537:105-106. 2022
- M173 Total imprecision of 8 high sensitivity cardiac troponin assays within sex-specific reference limits: Clinical implications. 530:S282-S282. 2022
- The imprecision for a high-sensitivity cardiac troponin assay and a CA 19-9 assay in samples with high C-reactive protein concentrations. 524:192-193. 2022
- Determination of 97.5th and 99th percentile upper reference limits for heart-type fatty acid-binding protein (H-FABP) in a US population. 523:397-401. 2021
- Low-risk cutoff of 90 ml/min/1.73 m2 for the estimated glomerular filtration rate and the importance of the equation for patients with acute coronary syndrome. 523:532-533. 2021
- Combination of lymphocyte count and not the serological response with high-sensitivity cardiac troponin for risk stratification in patients with possible COVID-19. 519:306-307. 2021
- The effect of the Covid-19 shutdown on glycemic testing and control. 519:148-152. 2021
- Detection of repeated positive result biases for a high-sensitivity cardiac troponin I assay. 510:242-243. 2020
- Analytical performance of cardiac troponin assays – Current status and future needs. 509:149-155. 2020
- Cautious interpretation of antiphospholipid antibodies in COVID-19. 509:166-166. 2020
- Macrocomplexes and high-sensitivity cardiac troponin assays in samples stored for over 15 years. 505:6-8. 2020
- Long-term quality control testing on a high-sensitivity cardiac troponin I assay. 498:27-29. 2019
- A post-hoc subgroup analysis assessing acute cardiac biomarker profiles in female cancer patients during adjuvant therapy. 495:355-357. 2019
- Between-day versus within-day imprecision using the Abbott high-sensitivity cardiac troponin I assay at concentrations around 5 ng/l. 489:58-60. 2019
- Evaluation of the Siemens ADVIA Centaur high-sensitivity cardiac troponin I assay in serum. 487:216-221. 2018
- Multicenter comparison of imprecision at low concentrations of two regulatory approved high-sensitivity cardiac troponin I assays. 486:219-220. 2018
- Performance of high-sensitivity cardiac troponin in the emergency department for myocardial infarction and a composite cardiac outcome across different estimated glomerular filtration rates. 479:166-170. 2018
- Relationships of kidney injury molecule-1 with renal function and cardiovascular risk factors in the general population. 478:13-17. 2018
- Analytical comparison of three different versions of a high-sensitivity cardiac troponin I assay over 10 years. 475:51-55. 2017
- A laboratory score at presentation to rule-out serious cardiac outcomes or death in patients presenting with symptoms suggestive of acute coronary syndrome. 469:69-74. 2017
- Negative interference of N-acetyl cysteine (NAC) on selected chemistries on the Abbott architect platform. 451:219-221. 2015
- Matrix and bilirubin interference for high-sensitivity cardiac troponin I. 442:49-51. 2015
- Variability of ethics education in laboratory medicine training programs: Results of an international survey. 442:115-118. 2015
- Centrifugation — an important pre-analytical factor for the Abbott Architect high-sensitivity cardiac troponin I assay. 436:273-275. 2014
- Analytical factors to consider when assessing a high-sensitivity cardiac troponin I assay compared to a contemporary assay in clinical studies. 429:6-7. 2014
- Considerations for establishing a reference interval for elderly individuals in the emergency department with the high-sensitivity cardiac troponin T assay. 421:85-86. 2013
- Comparison of hs-cTnI, hs-cTnT, hFABP and GPBB for identifying early adverse cardiac events in patients presenting within six hours of chest pain-onset. 419:39-41. 2013
- Sensitive and high sensitivity cardiac troponin I concentrations in the Heart Outcomes Prevention Evaluation (HOPE) study — A high risk population. 411:1832-1832. 2010
- Another potential marker linking gender and cardiac mortality: PAPP-A — A new marker in risk stratification for women presenting with chest pain. 408:139-140. 2009
- “Upstream markers” provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes. 387:133-138. 2008
- Authors' response to Apple editorial. 380:245-246. 2007
- Effects of contemporary troponin assay sensitivity on the utility of the early markers myoglobin and CKMB isoforms in evaluating patients with possible acute myocardial infarction. 380:213-216. 2007
- Detecting the polymorphisms of paraoxonase (PON) cluster in Chinese Han population based on a rapid method. 365:98-103. 2006
- Screening for the early detection of disease, the need for evidence. 315:5-15. 2002
- Some ethical and design challenges of screening programs and screening tests. 315:41-48. 2002
- Clinical and analytical considerations in the utilization of cholinesterase measurements. 237:91-105. 1995
- The diagnosis of inborn errors of metabolism by examination of the genotype. 217:3-14. 1993
- The widening horizons of bioanalytical mass spectrometry. 194:1-17. 1990
- Serum human chorionic gonadotrophin levels in early pregnancy. 181:281-292. 1989
- Is the ex vivo rat gastric chamber model suitable for studying the gastrotoxicity of refluxed duodenal contents? Initial results using deoxycholic acid. 178:313-325. 1988
- Liquid chromatographic determination of inhibition of monoamine oxidase activity in platelet rich plasma of depressed patients treated with phenelzine. 152:63-69. 1985
- Mass spectrometry and clinical chemistry. 139:231-294. 1984
- Liquid Chromatographie determination of urinary metanephrines after pre-column oxidation to vanillin. 135:143-150. 1983
- Fumaric aciduria: a new organic aciduria, associated with mental retardation and speech impairment. 132:301-308. 1983
- Analysis of chlorpromazine in plasma: Effect of specimen storage. 109:351-354. 1981
- The role of serum myoglobin in the detection and measurement of myocardial infarction. 106:17-28. 1980
- Comparison of infrared and wet chemical analysis of urinary tract calculi. 104:349-359. 1980
- Evaluation of an automated immunoassay procedure for APO-LDL for phenotyping type II hyperlipoproteinemia. 88:31-36. 1978
- Evaluation of the Vitatron Automatic Kinetic Enzyme System. 64:155-164. 1975
- Normal values at 37° for serum lactate dehydrogenase, α-hydroxybutyrate dehydrogenase and glycerate dehydrogenase. 46:5-10. 1973
- Effects of temperature and substrate concentration on the LDH/α-HBD ratio in heart and liver disease. 43:397-403. 1973
- Quantitative estimation of tryptophan in plasma and urine using thin-layer chromatography (TLC) and induced fluorescence. 17:317-323. 1967
- An improved technique for continuous in vivo analysis of glucose.. 14:386-390. 1966